A 2022 consensus report from the American Diabetes Association recommended annual testing of N-terminal pro-B-type natriuretic peptide (NT-proBNP) among patients with T2DM to facilitate early detection of HF [6]. This evidence concerns the gene NPPB and diabetes mellitus.